Immuneering reports 17.3-month survival in pancreatic cancer trial
Go back to Immuneering reports 17.3-month survival in pancreatic cancer trial| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.85 -0.14 (2.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.99 | 52 Week High | $0.04 | |||
| Open | $4.90 | 52 Week Low | $0.00 | |||
| Day High | $4.99 | P/E | N/A | |||
| Day Low | $4.84 | EPS | $-0.09 | |||
| Volume | 435,155 | |||||
| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 36.19 +0.14 (0.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.05 | 52 Week High | $66.55 | |||
| Open | $36.52 | 52 Week Low | $37.82 | |||
| Day High | $36.55 | P/E | N/A | |||
| Day Low | $35.85 | EPS | $0.00 | |||
| Volume | 3,515,658 | |||||
